JP2008539182A5 - - Google Patents

Claims (31)

  A multivalent HPV vaccine comprising L1 protein derived from HPV16, HPV18, and at least one other oncogenic HPV type, or an immunogenic fragment thereof, selected from the group consisting of HPV31, HPV45, and HPV52 The above vaccine, wherein the L1 protein or immunogenic fragment thereof derived from one or more HPV types is excluded from the vaccine, and the vaccine provides protection against infection caused by the excluded HPV type.   The vaccine according to claim 1, wherein the L1 protein derived from HPV31 or an immunogenic fragment thereof is excluded from the vaccine.   The vaccine according to claim 1, wherein L1 protein derived from HPV45 or an immunogenic fragment thereof is excluded from the vaccine.   The vaccine according to claim 1, wherein the L1 protein derived from HPV52 or an immunogenic fragment thereof is excluded from the vaccine.   The vaccine according to claim 1, wherein the L1 protein derived from HPV31 and HPV45 or an immunogenic fragment thereof is excluded from the vaccine.   The vaccine according to claim 1, wherein the L1 protein derived from HPV31 and HPV52 or an immunogenic fragment thereof is excluded from the vaccine.   The vaccine according to claim 1, wherein the L1 protein derived from HPV45 and HPV52 or an immunogenic fragment thereof is excluded from the vaccine.   The vaccine according to claim 1, wherein the L1 protein derived from HPV31 and HPV45 and HPV52 or an immunogenic fragment thereof is excluded from the vaccine.   The vaccine according to claim 1, wherein the vaccine protects against accidental infection.   2. A vaccine according to claim 1 wherein the vaccine protects against persistent infection.   The vaccine according to claim 1, wherein the other oncogenic HPV type is HPV33.   The vaccine according to claim 1, wherein the other oncogenic HPV type is HPV58.   The vaccine according to claim 1, wherein the other oncogenic HPV type is HPV59.   The HPV16 L1 protein or an immunogenic fragment thereof, the HPV18 L1 protein or an immunogenic fragment thereof, the HPV33 L1 protein or an immunogenic fragment thereof, and the HPV58 L1 protein or an immunogenic fragment thereof. The vaccine described.   The vaccine according to claim 1, wherein at least one of the L1 proteins or fragments thereof is in the form of virus-like particles.   The vaccine according to claim 1, wherein at least one of the L1 proteins is a truncated L1 protein.   The vaccine according to claim 16, wherein the at least one L1 protein is a C-terminal truncated L1 protein.   The vaccine of claim 1 further comprising an adjuvant.   19. A vaccine according to claim 18 wherein the adjuvant is an aluminum salt.   20. A vaccine according to claim 19, wherein the adjuvant is aluminum hydroxide.   19. A vaccine according to claim 18 wherein the adjuvant is 3D MPL.   19. A vaccine according to claim 18 wherein the adjuvant is 3D MPL and aluminum hydroxide.   The vaccine according to claim 18, wherein the adjuvant is an oil-in-water emulsion.   24. The vaccine of claim 23, wherein the adjuvant further comprises an aluminum salt.   A method for producing a vaccine according to claim 1, comprising combining LV protein derived from HPV16, HPV18, and at least one other oncogenic HPV type or an immunogenic fragment thereof, The above method, wherein the vaccine does not contain any of the L1 protein derived from one or more HPV types selected from the group consisting of HPV31, HPV45, and HPV52 and immunogenic fragments thereof.   Use of a composition comprising HPV16 L1 and HPV18 L1 proteins or immunogenic fragments thereof in the preparation of a medicament for the prevention of infection and / or disease caused by one or more of HPV31, HPV45, or HPV52 .   Use of a vaccine comprising HPV16 L1 protein or an immunogenic fragment thereof in the preparation of a medicament for the prevention of infection and / or disease caused by HPV31 or HPV52 or a combination thereof.   Use of a vaccine composition comprising HPV18 L1 protein or an immunogenic fragment thereof in the preparation of a medicament for the prevention of infection and / or disease caused by HPV45. 27. Use of a vaccine according to claim 26 in the manufacture of a medicament for the prevention of cytological abnormalities in an individual caused by a type other than HPV16 and HPV18 or for reducing the frequency of occurrence of cytological abnormalities. 27. Use of a vaccine or combination according to claim 26 in the manufacture of a medicament for the prevention of histologically confirmed CIN lesions (CIN1, CIN2, CIN3) caused by types other than HPV16 and HPV18. The composition comprises LV protein derived from HPV16, HPV18, and at least one other oncogenic HPV type, or an immunogenic fragment thereof, selected from the group consisting of HPV31, HPV45, and HPV52 The L1 protein or immunogenic fragment thereof derived from the above HPV types is excluded from the vaccine, and the vaccine provides protection against infections and / or diseases caused by the excluded HPV types. the use according to any one of 26-30.